Combined TET2/NRAS mutations drive myeloid leukemia, 5-Aza resistance and MEK inhibitor sensitivity

Hiroyoshi Kunimoto

Presentation information

Oral Session

Oral Session 1-11D MDS: Basic (2)

Fri. Oct 12, 2018 4:20 PM - 5:20 PM No.11 (Osaka International Convention Center, 10F 1004-5)

Chair: Hironori Harada (Tokyo University of Pharmacy and Life Sciendes, Japan)

[OS1-11D-1] Combined TET2/NRAS mutations drive myeloid leukemia, 5-Aza resistance and MEK inhibitor sensitivity

Hiroyoshi Kunimoto¹, Hideaki Nakajima¹, Ross Levine^2,3, Alan Shih^2,3 (1.Hematol., Yokohama City Univ., Yokohama, Japan, 2.HOPP, Memorial Sloan Kettering Cancer Center, New York, USA, 3.Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, USA)

Abstract password authentication.
Password is written on a program and abstract book.